|
US2010069397A1
|
|
Sexual dysfunction compounds
|
|
US2007163610A1
|
|
Formulation and Use and Manufacture Thereof
|
|
AU2006225269A1
|
|
Prefilled ampoules and manufacture thereof
|
|
AU2005242146A1
|
|
Liquid delivery device and method for operating an ejecting device
|
|
DK200401645A
|
|
Topical compsn. for treating glaucoma or ocular hypertension - comprises prostaglandin deriv. with omega side chain contg. ring structure
|
|
US7122515B2
|
|
Methods for treating a patient having Metabolic Syndrome
|
|
TW200423959A
|
|
New formulations and use thereof
|
|
AU2003255202A1
|
|
Prefilled ampoules and manufacture thereof
|
|
AU2003260817A8
|
|
System and method for evaluating the cost-effectiveness of providing growth hormone replacement therapy
|
|
WO2004012702A1
|
|
New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
|
|
TW200407142A
|
|
New formulation and use thereof
|
|
SE0300520D0
|
|
A container containing nicotine and its use and manufacture
|
|
MXPA04003866A
|
|
Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder.
|
|
IL160852D0
|
|
Pharmaceutical compositions for the treatment of urinary disorders
|
|
PL370037A1
|
|
Pharmaceutical composition
|
|
WO03026655A1
|
|
New formulations and use thereof
|
|
BR0212834A
|
|
Formulations and use thereof
|
|
GB0218912D0
|
|
Metabolic syndrome
|
|
GB0215188D0
|
|
Height-related gene
|
|
MXPA03011557A
|
|
A coated nicotine-containing chewing gum, manufacture and use thereof.
|
